Events Archives - Page 73 of 128

4 minute read

Sernova’s Cell Pouch System with Evotec’s iPSC-Derived Islet-like Clusters For Type 1 Diabetes Presented At The 4th IPITA / HSCI / JDRF Summit

April 24, 4:20 PM

Evotec's scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and

EVO

1 minute read

Adverum Biotechnologies Presented Nonclinical Data Sunday at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

By Charles Gross

April 23, 7:29 PM

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced nonclinical data supporting the two doses of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) being evaluated in the Phase 2 LUNA trial and the potential for staggered, bilateral administration in the treatment of wet AMD.

ADVM

2 minute read

EXCLUSIVE: Fireside With Enveric Biosciences’s Dr. Tucker, Unlocking Psychedelic Healing Benefits

By Joana Scopel

April 20, 5:02 PM

Recently, at the Benzinga Psychedelic Capital Conference, leading experts from the biotech and pharmaceutical industry gathered to discuss the remarkable potential of psychedelics in medicine.

ENVB

2 minute read

Salarius Pharmaceuticals Presents Compelling Data In Two SP-3164 Targeted Protein Degrader Posters At The American Association For Cancer Research Annual Meeting

By Benzinga Newsdesk

April 20, 8:47 AM

SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myelomaPreclinical findings support the Company's planned clinical

SLRX

3 minute read

ContraFect Data Presentations At The 33rd Annual ECCMID Meeting Highlight The Potential Efficacy Of Lysin CF-370 Against Antibiotic Resistant Gram-Negative Pathogens

By Benzinga Newsdesk

April 20, 8:47 AM

ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the

CFRX

3 minute read

Catalyst Pharmaceuticals Announces Third-Party Abstracts On FYCOMPA® To Be Presented At The Upcoming American Academy Of Neurology 2023 Annual Meeting

By Benzinga Newsdesk

April 20, 8:33 AM

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients

CPRX

1 minute read

Precision BioSciences To Present Preclinical In Vivo Gene Editing Research For Its ARCUS HBV Program At Upcoming Global Hepatitis Summit 2023

By Benzinga Newsdesk

April 20, 8:11 AM

- Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis BPrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing

DTIL

2 minute read

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19

By Benzinga Newsdesk

April 20, 8:07 AM

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Michigan Medicine, a part of the

VTVT

1 minute read

AI Rollout, Plus New Partnerships For Snap: What’s Going On?

By Adam Eckert

April 19, 2:51 PM

Snap Inc (NYSE SNAP) shares are trading higher Wednesday amid the company's 2023 Partner Summit event in which it touted new partnerships and unveiled new AI features for Snapchat. What Happened: Snap highlighted new partners and its latest innovations at an event on Wednesday.

3 minute read

EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps

By Lara Goldstein

April 19, 10:04 AM

In the current psychedelics landscape, one of the most important topics is compound legality. While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business?

AWKNF